Hibiscus Sabdariffa Extract Effect on Neuromuscular Performance
RECUPERA-T
1 other identifier
interventional
25
1 country
2
Brief Summary
Exercise-induced muscle damage (EIMD) is a transient problem that athletes face after performing more intense and/or prolonged exercise than they are used to. EIMD is accompanied by an increase in the production of reactive oxygen species and a decrease in the antioxidant capacity of the organism. This phenomenon decreases the performance capacity of athletes due to impaired muscle strength and range of motion. Among the strategies to reduce EIMD, the use of nutritional strategies rich in antioxidants such as polyphenols stands out. In this sense, the extract of Hibiscus sabdariffa is particularly rich in polyphenolic antioxidants, among which anthocyanins stand out. Previous studies have concluded that the administration of an extract of Hibiscus sabdariffa can prevent overtraining syndrome by reducing the levels of oxidizing agents and increasing the body's antioxidant defenses. However, despite the fact that Hibiscus sabdariffa extract has been shown to be safe for humans to ingest and have various health benefits, to our knowledge, no studies have evaluated its ability to minimize neuromuscular performance impairment that occurs after performing an intense session of strength training. Based on previous evidence, we hypothesize that supplementation with an extract of Hibiscus sabdariffa will improve neuromuscular performance after performing intense resistance exercise in young (18-35 years) and trained adults, with at least 1 year of experience training. strength. The design of this study is crossover, randomized and placebo controlled, where each individual will act as her own control. The neuromuscular performance parameters to be evaluated will be: i) explosive strength - main variable, in terms of countermovement jump height (CMJ); ii) the maximum dynamic force; and iii) the ability to change direction, all of them 24h and 72h after a high-intensity strength training session. If our hypothesis is confirmed, the results of our study would not only have an impact at a scientific level but also at a commercial level through the development of supplements and/or functional foods.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2023
Shorter than P25 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 28, 2022
CompletedFirst Posted
Study publicly available on registry
December 16, 2022
CompletedStudy Start
First participant enrolled
January 23, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2023
CompletedJanuary 26, 2023
January 1, 2023
2 months
November 28, 2022
January 24, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Explosive strength
It will be measured through the height of the countermovement jump (CMJ)
1 day (24h) after a bout of an intense resistance exercise
Maximal dynamic force
It will be measured by means of a CMJ with a load
1 day (24h) after a bout of an intense resistance exercise
Ability to change direction
It will be measured by means of a CMJ with a load
1 day (24h) after a bout of an intense resistance exercise
Secondary Outcomes (3)
Explosive strength
3 days (72h) after a bout of an intense resistance exercise
Maximal dynamic force
3 days (72h) after a bout of an intense resistance exercise
Ability to change direction
3 days (72h) after a bout of an intense resistance exercise
Study Arms (2)
Placebo
PLACEBO COMPARATORMicrocrystalline cellulose
Hibiscus sabdariffa extract
EXPERIMENTAL520 mg of Hibiscus sabdariffa extract
Interventions
Daily supplementation with 520 mg of Hibiscus sabdariffa extract for 10 days.
Eligibility Criteria
You may qualify if:
- Age: 18-35 years.
- Body mass index: 18.5-30 kg/m2
- Be able to understand the instructions, objectives, and protocol of the study.
- Trained in some force sports discipline ≥1 year prior to the study and accustomed to carrying out the exercises of the evaluation protocol.
You may not qualify if:
- History of a major adverse cardiovascular event, renal failure, cirrhosis, eating disorder, polycystic ovarian syndrome, weight control surgery, type 2 diabetes mellitus, or HIV/AIDS.
- Any chronic pathology in which the intake of nutritional supplements is not recommended.
- Any condition that, in the investigator's judgment, impairs the ability to participate in the study or represents a personal risk to the participant.
- Use of medications that may affect the results of the study.
- Unstable body weight for 3 months prior to study start (\>4 kg weight gain or loss)
- Routine use of teas/infusions/supplements rich in polyphenols.
- Pregnancy and lactation.
- Active tobacco or illicit drug use or history of treatment for alcohol abuse.
- To be on a special diet or prescribed for other reasons (eg celiac disease).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Instituto Mixto Universitario Deporte y Salud (iMUDS)
Granada, 18007, Spain
Facultad de Ciencias del Deporte
Granada, 18071, Spain
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- triple-blinded
- Purpose
- PREVENTION
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
November 28, 2022
First Posted
December 16, 2022
Study Start
January 23, 2023
Primary Completion
April 1, 2023
Study Completion
June 1, 2023
Last Updated
January 26, 2023
Record last verified: 2023-01
Data Sharing
- IPD Sharing
- Will not share